Sarah Rumple Mahan
Editor-In-Chief
Sarah Rumple Mahan is an award-winning veterinary writer and editor living in Denver, Colorado. Sarah has written for Today’s Veterinary Business since 2018, and she became the publication’s editor-in-chief in 2026. Reach her at smahan@navc.com.

Vetoquinol USA has received approval from the U.S. Food and Drug Administration (FDA) for Felpreva, a new broad-spectrum parasiticide for cats.
According to Vetoquinol, the prescription topical solution is indicated for feline patients at least 6 months of age and weighing at least 2.2 pounds. The product’s formulation combines three active ingredients — emodepside, praziquantel, and tigolaner — designed to simplify parasite management by requiring only four applications annually. The clinical coverage includes:
- External parasites: Treats and prevents fleas and controls black-legged ticks for 12 weeks; treats and controls lone star ticks for eight weeks, while also controlling mites.
- Internal parasites: Treats roundworms and tapeworms.
Michael Maginnis, country manager at Vetoquinol USA, said the new product aims to simplify parasite control by providing “fewer applications with broad-spectrum treatment and control.” Felpreva is expected to be available through distributors by 2027.
